Techniques for Diagnosing Neuroendocrine Tumors

Video

For High-Definition, Click

The diagnosis of neuroendocrine tumors comes with several inherent challenges, including the identification of type and primary site. To address this, several specialized imaging techniques are available, such as octreotide scans.

In general, Pamela L. Kunz, MD, notes that she generally begins with cross-sectional imaging using a multiphasic contrast-enhanced CT or MRI. She adds that as more data become available on novel therapeutics, the need to conduct an octreotide scan increases. Additionally, if more information is needed regarding the primary site of the tumor an octreotide scan may be required.

In many cases, several diagnostic tests are performed in an attempt to identify the primary site of the tumor, moderator Matthew H. Kulke, MD, points out. Rodney F. Pommier, MD, believes these efforts are completely necessary, as different treatments become available based on the type of tumor. In general, identifying the tumor type and primary site becomes more crucial, as new trials form and agents are approved.

Related Videos
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ilyas Sahin, MD
Arya Amini, MD
Adrianna Masters, MD, PhD,
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Riccardo Lencioni, MD, FSIR, EBIR
Manish A. Shah, MD
Chul Kim, MD, MPH